Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.681
+0.161 (10.57%)
Jun 6, 2025, 2:54 PM - Market open
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$1,139,225
Profits / Employee
-$2,556,935
Market Cap
19.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MRKR News
- 17 days ago - Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma - GlobeNewsWire
- 18 days ago - Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - GlobeNewsWire
- 2 months ago - Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - GlobeNewsWire
- 2 months ago - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - GlobeNewsWire
- 3 months ago - Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 6 months ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 6 months ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 6 months ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire